Roprostim/romigrastim and heltrombopag: a comprehensive comparison of two drugs for the treatment of ITP

In the field of treating idiopathic thrombocytopenia (ITP), Romiplostim/Romiplostim and Eltrombopag are two drugs that have attracted much attention. Although they both work to increase platelet counts by stimulating platelet production, the two show significant differences in many details. Next, we will analyze the similarities and differences between these two drugs in depth from multiple dimensions.

1. Molecular composition: Roprostim, as a recombinant human pegylated thrombopoietin (TPO), belongs to the category of protein drugs. Its molecular structure composed of amino acids has been specially processed to extend its effective time in the body, thereby optimizing the therapeutic effect. In contrast, Hetrombopag is a small molecule compound that has no structure related to natural thrombopoietin. It relies on different pathways to activate platelet production, and its small molecule properties allow patients to easily ingest it orally.

2. Principle of action: Ropremilast simulates the function of physiological thrombopoietin in the body by activating megakaryocyte receptors in the bone marrow, thereby promoting platelet production. Hatrombopag directly binds to the TPO receptor on megakaryocytes, promoting the differentiation of hematopoietic stem cells into megakaryocytes, ultimately increasing platelet production. These two different mechanisms of action may lead to differences in their efficacy and side effects.

3. Medication: Roprostim is usually administered by subcutaneous injection, usually once a week, under the guidance of a doctor. The dose will be adjusted accordingly according to the patient's platelet count. In contrast, Hetrombopag, as an oral drug, provides patients with a more convenient treatment method that can be taken at home. This undoubtedly increases the patient's medication compliance and makes the treatment process more flexible.

4. Applicable symptoms: Roprostim is excellent in the treatment of chronic idiopathic thrombocytopenic purpura (ITP) in adults. In some cases, it is also suitable for pediatric patients, but it needs to be used with caution and decisions based on specific circumstances. Hatrombopag has a wider scope of application. It can be used not only for the treatment of chronic ITP in adults and children, but also for other types of thrombocytopenia, such as thrombocytopenia caused by radiotherapy. This difference in indications makes the two drugs have their own merits in clinical application.

5. Side effects: When using Roprostim, patients may experience common side effects such as injection site reactions, headaches, and fatigue. Some patients may also face the risk of serious side effects such as thrombosis. Therefore, platelet levels need to be closely monitored during treatment. On the other hand, although Hetrombopag also has some side effects, such as nausea, abdominal pain and abnormal liver function, special attention needs to be paid to its potential hepatotoxicity, which requires strict monitoring of the patient's liver function during use.